The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Tanezumab’s Phase 3 Results for OA

Tanezumab’s Phase 3 Results for OA

June 25, 2019 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

MADRID—Tanezumab is a monoclonal antibody against nerve growth factor in clinical trials for treating osteoarthritis (OA) pain. Results from a phase 3, randomized, double-blind, placebo-controlled, 24-week study were presented during the 2019 European Congress of Rheumatology (EULAR), June 12–15.1

You Might Also Like
  • Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis
  • Tanezumab for OA Pain
  • Phase 3 Trials: Secukinumab for Psoriatic Arthritis & DA-DKP for OA
Also By This Author
  • FDA to Review Immediate-Release Oxycodone; Plus NICE Recommends Secukinumab

Study patients had moderate to severe knee or hip OA pain and no pain relief from, or experienced intolerance to, acetaminophen, oral non-steroidal anti-inflammatory drugs, tramadol or opioids. Patients were randomized to receive 2.5 mg or 5 mg of subcutaneous tanezumab or placebo at baseline and Weeks 8 and 16. Co-primary endpoints were the change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain, WOMAC Physical Function and Patient Global Assessment of OA (PGA-OA) scores at Week 24. The study also assessed safety.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Results
Patients receiving 5 mg of subcutaneous tanezumab met all co-primary endpoints. Patients treated with 2.5 mg of tanezumab met WOMAC Pain and Physical Function endpoints, but not the PGA-OA endpoint.

Adverse events and adverse event discontinuations were similar in the groups. Serious adverse events occurred more frequently in tanezumab-treated patients than in placebo-treated patients. Two deaths occurred in the group taking 5 mg of tanezumab, but they were not deemed treatment related.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Total joint replacements occurred in 7% of patients in the 5 mg tanezumab group, 7.8% of patients in the 2.5 mg tanezumab group and 6.7% of patients in the placebo group. Total joint replacements were primarily seen as normal OA progression (58/79; 73.4%). Pre-specified joint safety events occurred in the tanezumab-treated patients, which included rapidly progressive OA, subchondral insufficiency fracture and primary osteonecrosis.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Berenbaum F, Blanco FJ, Guermazi A, et al. Subcutaneous tanezumab for osteoarthritis pain: A 24-week phase 3 study with a 24-week follow up (LB0007). Ann Rheum Dis. 2019 Jun. 78(suppl 2):A262.

Filed Under: Analgesics, Drug Updates Tagged With: hip, knee, Knee Osteoarthritis (OA), osteoarthritis (OA), Pain, tanezumab

You Might Also Like:
  • Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis
  • Tanezumab for OA Pain
  • Phase 3 Trials: Secukinumab for Psoriatic Arthritis & DA-DKP for OA
  • Clinical Trials: Zilretta Promising for Knee OA Pain & Golimumab Completes Phase 3 Trial

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.